retatrutide phase 2 results obesity nejm 2023 (Eli Lilly's triple GLP-1/GIP/Glucagon receptor agonist) just delivered the most impressive + osteoarthritis data we've ever seen in the 3 TRIUMPH-4 trial: Weight Regain after Stopping Obesity

Switch compounds in the dropdowns to explore the full catalogue

Mounjaro, or tirzepatide, stands out due to its unique dual-action mechanism that activates both GLP-1 and GIP receptors

,

Ethics declarations Ethics approval and consent to participate The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Independent Institutional Ethics Committee of IRCCS MultiMedica, Milan (protocol code 24/2012(153))

ACT 2: Tirzepatide (Mounjaro & Zepbound) More Flexibility, Same Discipline Tirzepatide is a dual GIP/GLP-1 receptor agonist, making it pharmacologically distinct from semaglutide

Why GLP-1s Fix the Why Not Just the What GLP-1s are metabolic reset tools, not quick fixes